

**AMENDMENTS TO THE SPECIFICATION**

Page 1, immediately following the title "TARGET FOR B-CELL DISORDERS," please insert the following paragraph:

This application is a U.S. National Phase Application pursuant to 35 U.S.C. 371 of International Application No. PCT/AU2005/000280, which was filed February 28, 2005, claiming benefit of priority of United States Patent Application No. 60/548,118, which was filed February 27, 2004. The entire disclosure of each of the foregoing applications is incorporated herein by reference.

Page 46, immediately after claim 27, please insert a new page containing the following abstract of the application:

**ABSTRACT**

The present invention relates to the diagnosis treatment of B-cell disorders such as multiple myeloma (MM). In particular, the present invention relates to the treatment of B-cell disorders using ligands which bind to free lambda light chains expressed on the surface of lymphoid cancer cells.